亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Asymmetric Synthesis of Norcantharidin Analogues by Alkynylation of Oxabenzonorbornadienes and Their Anticancer Activities

总结: The present invention relates to chemical entities originated from natural sources or obtained from a chemically synthesized compound and further synthesized for therapeutic uses. More particularly, the present invention relates to norcantharidin analogues synthesized by a transition metal-catalyzed alkynylation of oxanorbornadiene derivatives and their antitumor effects.

技术优势: Reducing the side-effect in the urinary system to some extent and increasing the number of white blood cells with comparable anti-cancer activity

详细技术说明: The norcantharidin analogues of the present invention are originated from natural sources and further synthesized into at least three different compounds. using an Ir catalyst to carry out transition metal-catalyzed alkynylation of oxanorbornadiene derivatives.

附加资料: Inventor: Chan, Albert Sun-Chi | Fan, Baomin | Wang, Jun | Lin, Chengyuan | Huang, Chao | Yang, Qingjing | Xu, Jianbin | Bian, Zhaoxiang | Lu, Aiping | Hu, Jun
Priority Number: US8835658B2
IPC Current: C07D030700 | C07D049308
US Class: 549459
Assignee Applicant: Hong Kong Baptist University
Title: Asymmetric synthesis of norcantharidin analougus by alkynylation of oxabenzonorbornadienes and their anticancer activities
Usefulness: Asymmetric synthesis of norcantharidin analougus by alkynylation of oxabenzonorbornadienes and their anticancer activities
Summary: (I) is useful for treating cancer tumors including colorectal carcinoma and breast adenocarcinoma (all claimed). Test details are described but no results given.
Novelty: Synthesizing norcantharidin compounds, useful for treating cancer tumors e.g. colorectal carcinoma, comprises alkynylation of oxabenzonorbornadienes in presence of catalyst including transition metal compound and biaryl diphosphine ligand

欲了解更多信息，请点击这里